WO2016142708A3 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
WO2016142708A3
WO2016142708A3 PCT/GB2016/050645 GB2016050645W WO2016142708A3 WO 2016142708 A3 WO2016142708 A3 WO 2016142708A3 GB 2016050645 W GB2016050645 W GB 2016050645W WO 2016142708 A3 WO2016142708 A3 WO 2016142708A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lipid
provides
present
microparticles
Prior art date
Application number
PCT/GB2016/050645
Other languages
French (fr)
Other versions
WO2016142708A2 (en
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Limited
King, Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, King, Lawrence filed Critical Cipla Limited
Publication of WO2016142708A2 publication Critical patent/WO2016142708A2/en
Publication of WO2016142708A3 publication Critical patent/WO2016142708A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

The present invention provides a pharmaceutical composition comprising lipid microparticles comprising a lipid layer and at least one active pharmaceutical ingredient, wherein the at least one active pharmaceutical ingredient is adsorbed on the lipid microparticle. The present invention also provides a process for preparing the lipid microparticles and the associated pharmaceutical compositions. The pharmaceutical composition may be used in the treatment and/or prophylaxis of lung disease.
PCT/GB2016/050645 2015-03-10 2016-03-09 Pharmaceutical composition WO2016142708A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN770/MUM/2015 2015-03-10
IN770MU2015 2015-03-10

Publications (2)

Publication Number Publication Date
WO2016142708A2 WO2016142708A2 (en) 2016-09-15
WO2016142708A3 true WO2016142708A3 (en) 2016-12-29

Family

ID=55543006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2016/050645 WO2016142708A2 (en) 2015-03-10 2016-03-09 Pharmaceutical composition

Country Status (2)

Country Link
WO (1) WO2016142708A2 (en)
ZA (1) ZA201601656B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109077998B (en) * 2017-06-13 2023-02-03 恩康药业科技（广州）有限公司 Salmeterol lipid complex and preparation method thereof
CN109758437A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation Nintedanib freeze-dried lipidosome preparation and preparation method thereof
CN109758436A (en) * 2017-11-09 2019-05-17 北京盈科瑞创新药物研究有限公司 A kind of Neulized inhalation pirfenidone freeze-dried lipidosome preparation and preparation method thereof
CN108175764B (en) * 2017-12-19 2020-02-21 亿腾医药（苏州）有限公司 Preparation method of anhydrous beclomethasone dipropionate sterile powder and inhalation suspension thereof
US20210121432A1 (en) * 2018-04-17 2021-04-29 Université De Caen Normandie Bambuterol for the Treatment of Alzheimer's Disease
CN110742875B (en) * 2018-07-05 2022-09-30 北京盈科瑞创新药物研究有限公司 Pirfenidone solution preparation for inhalation and preparation method and application thereof
US11304901B2 (en) 2019-08-28 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Liposome formulation of fluticasone furoate and method of preparation
US11083693B1 (en) * 2020-01-20 2021-08-10 Cai Gu Huang Liposome formulation of vilanterol trifenatate
CN111729087A (en) * 2020-07-24 2020-10-02 成都大学 Lipid modifier of selective beta 2 receptor agonist and preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
WO2002083840A2 (en) * 2001-04-03 2002-10-24 Arizeke Pharmaceuticals, Inc. Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
WO2003079885A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US20040042970A1 (en) * 2002-03-20 2004-03-04 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
WO2014141135A1 (en) * 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CN105209013B (en) 2013-03-14 2019-04-26 诺华股份有限公司 Spray dried formulations are decrystallized through taking off for mixing by spraying

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
WO2002083840A2 (en) * 2001-04-03 2002-10-24 Arizeke Pharmaceuticals, Inc. Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
WO2003079885A2 (en) * 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US20040042970A1 (en) * 2002-03-20 2004-03-04 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
WO2014141135A1 (en) * 2013-03-14 2014-09-18 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug

Also Published As

Publication number Publication date
WO2016142708A2 (en) 2016-09-15
ZA201601656B (en) 2017-06-28

Similar Documents

Publication Publication Date Title
WO2016142708A3 (en) Pharmaceutical composition
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
EP3587422A4 (en) Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
WO2015077503A8 (en) Autotaxin inhibitor compounds
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
CN108026053A8 (en) Condensed glyoxaline compound as mIDH1 inhibitor
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
WO2016126085A3 (en) Heterocyclic compound and pharmaceutical composition comprising same
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2017048974A8 (en) Inhalable nicotine formulations, and methods of making and using thereof
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP3566702A4 (en) Pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy, comprising baicalein as active ingredient
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016178510A3 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
EP3260121A4 (en) Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16710486

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16710486

Country of ref document: EP

Kind code of ref document: A2